文章：

当前关于大B细胞淋巴瘤输注后CAR T细胞扩增与持久性的见解

Current Insights of Post-Infusion CAR T Expansion and Persistence for Large B-Cell Lymphoma

原文发布日期：29 September 2025

DOI: 10.3390/cancers17193167

类型: Article

开放获取: 是

英文摘要：

CD19 directed chimeric antigen receptor (CAR) T-cell therapy is standard of care for relapsed or refractory large B-cell lymphoma. CAR T-cell persistence and activity are associated with outcomes for patients with relapsed B-acute lymphoblastic leukaemia (B-ALL), but the association between expansion kinetics and outcome is less clear in the setting of large B-cell lymphoma. CAR T-cell expansion and persistence have been measured in both clinical trials and real-world settings, but the clinical relevance and applicability of these measurements remain unclear. There is increasing evidence that the in vivo kinetics of CAR T-cells post-infusion do offer important predictive insights into patient outcomes; despite this, limitations remain given the heterogeneity in methodology and timing of measurement. This review will summarise methodologies utilised to measure CD19 directed CAR T-cell expansion and persistence in vivo, in addition to the clinical implications of these measurements as currently described.

摘要翻译： 

CD19导向的嵌合抗原受体（CAR）T细胞疗法已成为复发或难治性大B细胞淋巴瘤的标准治疗方案。CAR T细胞的持续存在与活性与复发B细胞急性淋巴细胞白血病（B-ALL）患者的预后密切相关，但在大B细胞淋巴瘤中，其扩增动力学与预后的关联尚不明确。目前已在临床试验和真实世界环境中对CAR T细胞的扩增与持续存在进行了测量，但这些测量结果的临床相关性及适用性仍存在疑问。越来越多的证据表明，输注后CAR T细胞的体内动力学确实能为患者预后提供重要的预测信息；尽管如此，由于测量方法和时间点的异质性，相关研究仍存在局限性。本综述将总结目前用于测量CD19导向CAR T细胞体内扩增与持续存在的方法，并探讨这些测量结果的临床意义。

原文链接：

Current Insights of Post-Infusion CAR T Expansion and Persistence for Large B-Cell Lymphoma